Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Trial sponsor
BeiGene Australia Pty Ltd
Scientific Title
An International, Phase 2, Open-Label, Randomized Study of BGB-3111 Combined With Obinutuzumab Compared With Obinutuzumab Monotherapy in Relapsed/ Refractory Follicular Lymphoma